U.S. markets close in 1 hour 51 minutes

Organovo Holdings, Inc. (ONVO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
4.4202+0.0202 (+0.46%)
As of 02:02PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close4.4000
Bid4.4100 x 800
Ask4.4900 x 1800
Day's Range4.3074 - 4.5492
52 Week Range4.2500 - 23.9200
Avg. Volume55,922
Market Cap38.48M
Beta (5Y Monthly)0.55
PE Ratio (TTM)N/A
EPS (TTM)-1.3970
Earnings DateFeb 08, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for ONVO

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Organovo Holdings, Inc.
    ARWR: Lowering target price to $73.00ARROWHEAD PHARMACEUTICALS IN has an Investment Rating of HOLD; a target price of $73.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
    Fair Value
    Economic Moat
    4 days agoArgus Research
View more
  • GlobeNewswire

    Organovo On Track to Establish Human 3D Disease Model in Inflammatory Bowel Disease in 2022

    SAN DIEGO, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), today provided a business overview and progress update, and announced it is on track to establish its first models of inflammatory bowel disease in 2022 using its 3D bioprinting and other 3D tissue technologies. In September 2020, Organovo began its new business strategy after the vote of the stockholders brought a new Board of Directors into control. Since that time, Organovo has rebuilt the R&D function of the

  • GlobeNewswire

    Organovo Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum

    SOLANA BEACH, Calif., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), today announced that the Company’s annual meeting of shareholders, on September 14, 2021, at 9:00 a.m. was convened and adjourned, without any business being conducted, due to lack of the required quorum. A quorum consists of a majority of the shares entitled to vote. There were fewer than a majority of shares entitled to vote present, either in person or by proxy at this meeting. Approximately 45.6%

  • CNW Group

    /C O R R E C T I O N from Source -- RBC Global Asset Management Inc./

    RBC Global Asset Management Inc. ("RBC GAM Inc.") today announced June 2021 cash distributions for unitholders of RBC ETFs, as follows: